Dynamic informed consent processes vital for treatment with antidepressants

International Journal of Law and Psychiatry

Volumn 35, Issue 5-6, 2012, Pages 392-397

  Gopal, Abilash A ^a   Cosgrove, Lisa ^b   Shuv Ami, Itay ^c   Wheeler, Emily E ^b   Yerganian, Melissa J ^b   Bursztajn, Harold J ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Informed consent; Shared decision making

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PLACEBO; PROLACTIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BEHAVIOR DISORDER; BRAIN HEMORRHAGE; BREAST CANCER; CANCER RISK; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MALFORMATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL DECISION MAKING; DEPRESSION; DIABETES MELLITUS; DOCTOR PATIENT RELATION; DRUG FATALITY; DRUG INDUSTRY; DRUG INFORMATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ENDOCRINE DISEASE; FALLING; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLAUCOMA; HUMAN; HYPONATREMIA; INFORMED CONSENT; LIBIDO DISORDER; LIVER TOXICITY; LUNG TOXICITY; META ANALYSIS (TOPIC); METABOLIC DISORDER; MOTOR DYSFUNCTION; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUROTOXICITY; ORGASM DISORDER; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PULMONARY HYPERTENSION; RISK BENEFIT ANALYSIS; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SPONTANEOUS ABORTION; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; COMMUNICATION; FEMALE; HUMANS; INFORMED CONSENT; MALE; PATIENT PARTICIPATION; PROFESSIONAL-PATIENT RELATIONS;

EID: 84870540336     PISSN: 01602527     EISSN: 18736386     Source Type: Journal    
DOI: 10.1016/j.ijlp.2012.09.006     Document Type: Article

References (60)

1. American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder 2010, Author, Washington, DC, Available athttp://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485. Third Edition.
2. Andersohn F., Schade R., Suissa S., Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. The American Journal of Psychiatry 2009, 166(5):591-598.
3. Andreou C. Dynamic choice. The Stanford Encyclopedia of Philosophy 2008, Retrieved April 27, 2012, fromhttp://plato.stanford.edu/archives/fall2008/entries/dynamic-choice/. E.N. Zalta (Ed.).
4. Appelbaum P.S., Grisso T. Capacities of hospitalized, medically ill patients to consent to treatment. Psychosomatics 1997, 38(2):119-125.
5. Applbaum K. Getting to yes: Corporate power and the creation of a psychopharmaceutical blockbuster. Culture, Medicine and Psychiatry 2009, 33(2):185-215.
6. Aubert R.E., Stanek E.J., Yao J., Teagarden J.R., Subar M., Epstein R.S., et al. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Journal of Clinical Oncology 2009, 27(18s):cra508.
7. Avorn J., Choudhry N.K. Funding for medical education: Maintaining a healthy separation from industry. Circulation 2010, 121(20):2228-2234.
8. Azoluay L., Dell'Aniello S., Huiart L., du Fort G.G., Suissa S. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Research and Treatment 2011, 126(3):695-703.
9. Bahrick A.S., Harris M.M. Sexual side effects of antidepressant medications: An informed consent accountability gap. Journal of Contemporary Psychotherapeutics 2008, 39(2):135-143. 10.1007/s10879-008-9094-0.
10. Beauchamp T.L. Informed consent: Its history, meaning, and present challenges. Cambridge Quarterly of Healthcare Ethics 2011, 20:515-523. 10.1017/S0963180111000259.
11. Bekelman J., Li Y., Gross C. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 2003, 289:454-465.
12. Berndt E.R., Bhattacharjya A., Mishol D.N., Arcelus A., Lasky T. An analysis of the diffusion of new antidepressants: Variety, quality, and marketing efforts. The Journal of Mental Health Policy and Economics 2002, 5(1):3-19.
13. Bresalier R., Sandler R., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England Journal of Medicine 2005, 352(11):1092-1102.
14. Brodkey A.C. The role of the pharmaceutical industry in teaching psychopharmacology: A growing problem. Academic Psychiatry 2005, 29(2):222-229.
15. Bursztajn H.J., Chanowitz B., Gutheil T.G., Hamm R.M. Micro-effects of language on risk perception in drug prescribing behavior. The Bulletin of the American Academy of Psychiatry and the Law 1992, 20(1):59-66.
16. Bursztajn H.J., Chanowitz B., Kaplan E., Gutheil T.G., Hamm R.M., Alexander V. Medical and judicial perceptions of the risks associated with the use of antipsychotic medication. The Bulletin of the American Academy of Psychiatry and the Law 1991, 19(3):271-275.
17. Bursztajn H.J., Feinbloom R.I., Hamm R.M., Brodsky A. Medical choices, medical chances: How patients, families, and physicians can cope with uncertainty 1990, Routledge, New York.
18. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. The New England Journal of Medicine 2006, 354(6):579-587.
19. Clayton A., Keller A., McGarvey E.L. Burden of phase-specific sexual dysfunction with SSRIs. Journal of Affective Disorders 2006, 91(1):27-32.
20. Cosgrove L., Bursztajn H.J. Undoing undue industry influence: Lessons from psychiatry as psychopharmacology. Organizational Ethics 2007, 3:131-133.
21. Costagliola C., Parmeggiani F., Sebastiani A. SSRIs and intraocular pressure modifications: Evidence, therapeutic implications and possible mechanisms. CNS Drugs 2004, 18(8):475-484.
22. Dalton S.O., Sørensen H.T., Johansen C. SSRIs and upper gastrointestinal bleeding: What is known and how should it influence prescribing?. CNS Drugs 2006, 20(2):143-151.
23. Davies J.C., Jackson P.R., Ramsay L.E., Ghahramani P. Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients. Archives of Internal Medicine 2003, 163(5):592-600.
24. de Abajo F.J., Montero D., Rodríguez L.A., Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic & Clinical Pharmacology & Toxicology 2006, 98(3):304-310.
25. Deegan P.E., Drake R.E. Shared decision making and medication management in the recovery process. Psychiatric Services 2006, 57(11):1636-1639.
26. Diav-Citrin O., Shechtman S., Weinbaum D., Wajnberg R., Avgil M., Di Gianantonio E., et al. Paroxetine and fluoxetine in pregnancy: A prospective, multicentre, controlled, observational study. British Journal of Clinical Pharmacology 2008, 66(5):695-705.
27. Fava M. Weight gain and antidepressants. The Journal of Clinical Psychiatry 2000, 61(Suppl. 11):37-41.
28. Fergusson D., Doucette S., Glass K.C., Shapiro S., Healy D., Hebert P., et al. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomized controlled trials. British Medical Journal 2005, 330:396-399.
29. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., et al. Antidepressant drug effects and depression severity: A patient level meta-analysis. JAMA : The Journal of the American Medical Association 2010, 303(1):47-53.
30. Friedman L.S., Richter E.D. Relationship between conflicts of interest and research results. Journal of General Internal Medicine 2004, 19(1):51-56.
31. Gagnon M.A., Lexchin J. The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine 2008, 5(1):e1. 10.1371/journal.pmed.0050001.
32. Gartlehner G., Hansen R.A., Morgan L.C., Thaler K., Lux L., Van Noord M., et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: An updated meta-analysis. Annals of Internal Medicine 2011, 155(11):772-785.
33. Gopal A., Pirakitikulr D., Bursztajn H.J. Informed consent in neuropsychosocialpharmacology. Psychiatric Times 2005, 22(13):59-63.
34. Gunnell D., Saperia J., Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomized controlled trials submitted to the MHRA's safety review. British Medical Journal 2005, 330(7488):385-388.
35. Gutheil T.G., Bursztajn H.J., Brodsky A. Malpractice prevention through the sharing of uncertainty: Informed consent and the therapeutic alliance. The New England Journal of Medicine 1984, 311:49-51.
36. Haddad P.M., Dursun S.M. Neurological complications of psychiatric drugs: Clinical features and management. Human Psychopharmacology 2008, 23(Suppl. 1):15-26.
37. Hamm R.M. Automatic thinking. Encyclopedia of medical decision making 2009, Vol. I:45-49. Sage, Newbury Park, CA. M.W. Kattan (Ed.).
38. Hamm R.M. Irrational persistence in belief. Encyclopedia of medical decision making 2009, Vol. II:28-32. Sage, Newbury Park, CA. M.W. Kattan (Ed.).
39. Herrmann N. Use of SSRIs in the elderly: Obvious benefits but unappreciated risks. The Canadian Journal of Clinical Pharmacology 2000, 7(2):91-95.
40. Howland R.H. Publication bias and outcome reporting bias: Agomelatine as a case example. Journal of Psychosocial Nursing and Mental Health Services 2011, 49(9):11-14. 10.3928/02793695-20110809-01.
41. Kelly C.M., Juurlink D.N., Gomes T., Duong-Hua M., Pritchard K.I., Austin P.C., et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population based cohort study. British Medical Journal 2010, 340:c693.
42. Larkin M., Clifton E., de Visser R. Making sense of 'consent' in a constrained environment. International Journal of Law and Psychiatry 2009, 32(3):176-183.
43. Laugharne J., Davies A., Arcelus J., Bouman W.P. Informing patients about tardive dyskinesia: A survey of clinicians' attitudes in three countries. International Journal of Law and Psychiatry 2004, 27(1):101-108.
44. Linden M., Westram A. What do psychiatrists talk about with their depressed patients parallel to prescribing an antidepressant?. International Journal of Psychiatry in Clinical Practice 2011, 15(1):35-41.
45. Loke Y., Trivedi A.N., Singh S. Meta-analysis: Gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Alimentary Pharmacology & Therapeutics 2008, 27(1):31-40.
46. Looper K.J. Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics 2007, 48(1):1-9.
47. Louik C., Lin A.E., Werler M.M., Hernández-Díaz S., Mitchell A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. The New England Journal of Medicine 2007, 356(26):2675-2683.
48. Montejo-González A.L., Llorca G., Izquierfo J.A., Ledesma A., Bousoño M., Calcedo A., et al. SSRI-induced sexual dysfunction: Fluoxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of Sex & Marital Therapy 1997, 23(3):176-194.
49. Movig K.L., Leufkens H.G., Lenderink A.W., Egberts A.C. Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly. European Journal of Clinical Pharmacology 2002, 58(2):143-148.
50. Penston J. Patients' preferences shed light on the murky world of guideline-based medicine. Journal of Evaluation in Clinical Practice 2007, 13(1):154-159.
51. Pitrou I., Boutron I., Ahmed N., Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Archives of Internal Medicine 2009, 169:1756-1761.
52. Reeves R.R., Ladner M.E. Antidepressant-induced suicidality: An update. CNS Neuroscience & Therapeutics 2010, 16(4):227-234.
53. Richards J.B., Papaioannou A., Adachi J.D., Joseph L., Whitson H.E., Prior J.C., et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Archives of Internal Medicine 2007, 167(2):188-194.
54. Seidman S. Ejaculatory dysfunction and depression: Pharmacological and psychobiological interactions. International Journal of Impotence Research 2006, 18(Suppl. 1):S33-S38.
55. Shaughnessy A.F., Slawson D.C., Bennett J.H. Separating the wheat from the chaff: Identifying fallacies in pharmaceutical promotion. Journal of General Internal Medicine 1994, 9(10):563-568.
56. Spielmans G.I., Parry P.I. From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents. Bioethical Inquiry 2010, 7(1):13-29. 10.1007/s11673-010-9208-8.
57. Spina E., Santoro V., D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clinical Therapeutics 2008, 30(7):1206-1227.
58. Tuccori M., Testi A., Del Tacca M., Antonioli L., Fornai M., Montagnani S., et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A review. Clinical Therapeutics 2009, 31(1):1426-1453.
59. Wolfe S.M. Early signals of harmful drugs. Archives of Internal Medicine 2012, 172(1):73-74.
60. Ziere G., Dieleman J.P., van der Cammen T.J., Hofman A., Pols H.A., Stricker B.H. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. Journal of Clinical Psychopharmacology 2008, 28(4):411-417.